Patents by Inventor Stjepan Jelakovic

Stjepan Jelakovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9611290
    Abstract: The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: April 4, 2017
    Assignee: THE MEDICINES COMPANY (LEIPZIG) GMBH
    Inventors: Peter Herold, Mohammed Daghish, Stjepan Jelakovic, Friedrich-Alexander Ludwig, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz
  • Publication number: 20140073573
    Abstract: The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds.
    Type: Application
    Filed: October 31, 2013
    Publication date: March 13, 2014
    Applicant: THE MEDICINES COMPANY (LEIPZIG) GMBH
    Inventors: Peter HEROLD, Mohammed DAGHISH, Stjepan JELAKOVIC, Friedrich-Alexander LUDWIG, Claudia REICHELT, Alexander SCHULZE, Andrea SCHWEINITZ
  • Patent number: 8598206
    Abstract: The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: December 3, 2013
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Peter Herold, Mohammed Daghish, Stjepan Jelakovic, Friedrich-Alexander Ludwig, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz
  • Patent number: 8497245
    Abstract: The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(?O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 30, 2013
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Peter Herold, Stjepan Jelakovic, Mohammed Daghish, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz, Friedrich-Alexander Ludwig, Adel Rafai Far, Ting Kang
  • Publication number: 20120252743
    Abstract: The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(?O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 4, 2012
    Applicant: The Medicines Company (Leipzig) GmbH
    Inventors: Peter Herold, Stjepan Jelakovic, Mohammed Daghish, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz, Friedrich-Alexander Ludwig, Adel Rafai Far, Ting Kang
  • Publication number: 20120115859
    Abstract: The application relates to novel substituted piperidines of the general formula (II) in which R1?, R2?, R2?, R4?, X, Z, m and n have the meanings defined in the description, to a process for the preparation thereof and to the use of these compounds as medicines, especially as renin inhibitors.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 10, 2012
    Inventors: Peter HEROLD, Robert Mah, Vincenzo Tschinke, Nathalie Jotterand, Dirk Behnke, Aleksandar Stojanovic, Stefan Stutz, Michael Quirmbach, Stjepan Jelakovic
  • Patent number: 8138176
    Abstract: Heterocyclic compounds of the formula (I) and salts, preferably pharmaceutically acceptable salts thereof, are provided in which R, R1, R2, Q, m and n have the meanings explained in detail in the description. Also provided are a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: March 20, 2012
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Aleksandar Stojanovic, Christiane Marti, Stjepan Jelakovic, Stefan Stutz
  • Patent number: 8138179
    Abstract: Novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R1, R1?, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: March 20, 2012
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Aleksandar Stojanovic, Christiane Marti, Stjepan Jelakovic, Bibia Bennacer, Stefan Stutz
  • Publication number: 20110301196
    Abstract: The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds.
    Type: Application
    Filed: January 28, 2011
    Publication date: December 8, 2011
    Applicant: The Medicines Company (Leipzig) GmbH
    Inventors: Peter HEROLD, Mohammed DAGHISH, Stjepan JELAKOVIC, Friedrich-Alexander LUDWIG, Claudia REICHELT, Alexander SCHULZE, Andrea SCHWEINITZ
  • Patent number: 8071651
    Abstract: Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH2—; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R2 is C1-6alkyl or C3-6cycloalkyl; R3 is independently of one another H, C1-6alkyl, C1-6alkoxycarbonyl or C1-6alkanoyl; R4 is C2-6alkenyl, C1-6alkyl, unsubstituted or substituted aryl-C1-6alkyl or C3-8cycloalkyl; R5 is -Lm-R6; L is C1-6alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: December 6, 2011
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stefan Stutz, Aleksandar Stojanovic, Christiane Marti, Dirk Behnke, Stjepan Jelakovic
  • Patent number: 8058307
    Abstract: Compounds of the general formula (formula I) in which the meanings of the substituents R1 to R6 are as indicated in claim 1, have renin-inhibiting properties and can be used as medicines.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: November 15, 2011
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stefan Stutz, Aleksandar Stojanovic, Stjepan Jelakovic, Christiane Marti
  • Patent number: 8022068
    Abstract: The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: September 20, 2011
    Assignee: Novartis AG
    Inventors: Dirk Behnke, Peter Herold, Stjepan Jelakovic, Robert Mah, Vincenzo Tschinke
  • Patent number: 8022069
    Abstract: The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: September 20, 2011
    Assignee: Novartis AG
    Inventors: Dirk Behnke, Peter Herold, Stjepan Jelakovic, Robert Mah, Vincenzo Tschinke
  • Publication number: 20110212950
    Abstract: The application relates to 4,4-disubstituted piperidines of the general formula (I) and their salts, preferably their pharmaceutically acceptable salts, in which R2, has the meanings explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.
    Type: Application
    Filed: October 24, 2008
    Publication date: September 1, 2011
    Applicant: NOVARTIS AG
    Inventors: Dirk Behnke, Peter Herold, Stjepan Jelakovic, Nathalie Jotterand, Isabelle Lyothier, Robert Mah, Stefan Stutz, Vincenzo Tschinke
  • Patent number: 8003640
    Abstract: The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which in which R1 has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: August 23, 2011
    Assignee: Novartis AG
    Inventors: Peter Herold, Stjepan Jelakovic, Robert Mah, Vincenzo Tschinke
  • Publication number: 20110144197
    Abstract: Compounds of the general formula (formula I) in which the meanings of the substituents R1 and R6 are as indicated in claim 1, have renin-inhibiting properties and can be used as medicines.
    Type: Application
    Filed: February 18, 2011
    Publication date: June 16, 2011
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stefan Stutz, Aleksandar Stojanovic, Stjepan Jelakovic, Christiane Marti
  • Publication number: 20110092492
    Abstract: Heterocyclic compounds of the formula (I) and salts, preferably pharmaceutically acceptable salts thereof, are provided in which R, R1, R2, Q, m and n have the meanings explained in detail in the description. Also provided are a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.
    Type: Application
    Filed: December 22, 2010
    Publication date: April 21, 2011
    Inventors: Peter HEROLD, Robert Mah, Vincenzo Tschinke, Aleksandar Stojanovic, Christiane Marti, Stjepan Jelakovic, Stefan Stutz
  • Publication number: 20110053924
    Abstract: The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.
    Type: Application
    Filed: February 6, 2009
    Publication date: March 3, 2011
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stjepan Jelakovic, Dirk Behnke
  • Patent number: 7879847
    Abstract: The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof in which R, R1, R2, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: February 1, 2011
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Aleksandar Stojanovic, Christiane Marti, Stjepan Jelakovic, Stefan Stutz
  • Publication number: 20110009399
    Abstract: The application relates to trisubstituted piperidines of the general formula (I) and their salts, preferably their pharmaceutically acceptable salts, in which R1, R2?, X, U, W, m and n have the meanings explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.
    Type: Application
    Filed: December 12, 2008
    Publication date: January 13, 2011
    Inventors: Peter Herold, Stjepan Jelakovic, Robert Mah, Dirk Behnke, Stefan Stutz, Vincenzo Tschinke, Nathalie Jotterand